Supercharged immune cells take on tough kidney tumors
NCT ID NCT07072234
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment for advanced clear cell kidney cancer that has stopped responding to standard therapies. The treatment uses donor immune cells (NK cells) that are genetically modified to better recognize and attack cancer cells while resisting the tumor's defenses. About 30 participants will receive this therapy to evaluate its safety and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Drug cocktail aims to shrink kidney tumors before surgery and prevent return
- Smart bomb for kidney cancer: imaging and radiation combo targets tough tumors
- Personalized vaccine trains immune system to attack kidney cancer blood vessels